Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. FDA approves Eliquis label expansion

      Headlines

      Thu, 21 Aug 2014

      patients with nonvalvular atrial fibrillation . In 2007, Bristol - Myers Squibb ( BMY ) and Pfizer ( PFE -0.3% ) entered into a global ..... commercialize apixaban, an oral anticoagulant discovered by BMY . Post your comment!

    2. UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots

      Headlines

      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Bristol - Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and...

    3. FDA OKs use of Eliquis to treat leg, lung clots

      Headlines

      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Bristol - Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

    4. Bristol - Myers and Celgene team up in cancer combo regimen

      Headlines

      Wed, 20 Aug 2014

      Bristol - Myers Squibb (NYSE: BMY ) and Celgene (NASDAQ: CELG ) collaborate in a Phase 1 clinical ..... tolerability and preliminary efficacy of a combination regimen of Bristol - Myers ' Opdivo (nivolumab) and Celgene's Abraxane (paclitaxel

    5. Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

      Headlines

      Tue, 12 Aug 2014

      immuno-oncology, labeled "I-O" first by Bristol - Myers Squibb Co . (NYSE: BMY ), has emerged to become a new class of cancer ..... are occupied by Merck & Co. (NYSE: MRK ), Bristol - Myers , AstraZeneca PLC (NYSE: AZN ) and Roche Holding

    6. New Morningstar Analyst Report for Bristol-Myers Squibb Company

      Stock Reports

      Tue, 12 Aug 2014

      believe a large portion of Bristol 's current valuation ..... clinical data are poor. Bristol carries a high price ..... upcoming patent losses. Bristol 's growth prospects ..... reinvestment in the business. Bristol - Myers Squibb discovers, develops

    7. Bristol-Myers Squibb forms drug development JV

      Headlines

      Mon, 4 Aug 2014

      Allied Minds and Bristol - Myers Squibb ( BMY +0.1% ) form Allied- Bristol Life Sciences LLC to identify ..... clinical candidate is identified, Bristol - Myers will have the option to acquire

    8. New Morningstar Analyst Report for Mead Johnson Nutrition Co

      Stock Reports

      Mon, 4 Aug 2014

      America, while the remainder comes from the United States and Europe. Mead Johnson operated as a subsidiary of Bristol - Myers Squibb from 1967 until it was spun off in 2009. We like Mead Johnson's infant nutrition-focused strategy, but it

    9. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Mon, 4 Aug 2014

      Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's Avastin and Eli Lilly and Bristol - Myers Squibb 's Erbitux. If Kyprolis fails in head-to-head studies against leading proteasome inhibitor Velcade, Amgen

    10. Incyte 2Q Results as Expected; Despite Pipeline Progress Shares Remain Fully Valued

      Commentary

      Thu, 31 Jul 2014

      checkpoint inhibitor MPDL3280A in lung cancer patients. This follows similar deals with AstraZeneca, Merck, and Bristol - Myers Squibb , which are all focused on the potential for synergistic effects with other immuno-oncology products. We believe

    « Prev12345Next »
    Content Partners